PLXPQ — PLx Pharma Winddown Income Statement
0.000.00%
- $0.00m
- -$9.82m
- $8.21m
- 18
- 83
- 11
- 30
Annual income statement for PLx Pharma Winddown, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.779 | 0.753 | 0.565 | 0.03 | 8.21 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 3.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.6 | 11.7 | 14.8 | 13.5 | 49 |
Operating Profit | -15.8 | -11 | -14.2 | -13.5 | -40.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -16.3 | 0.896 | -20.5 | -15.2 | -46.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -15.3 | 0.896 | -20.5 | -15.2 | -46.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -15.3 | 0.896 | -20.5 | -15.2 | -46.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -15.3 | 0.896 | -34.3 | -16.9 | -48.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.97 | 0.103 | -3.84 | -1.74 | -2.06 |